Table 6.

Model performance metrics for incident and resolved neuropathic pain

Aspect	Measure	Incident neuropathic pain		Resolved neuropathic pain
		Internal validation	External validation	Internal validation	External validation
Performance	Nagelkerke R2	0.091 (0.088–0.093)	0.038 (0.035–0.042)	0.291 (0.277–0.310)	0.148 (0.139–0.161)
Discrimination	AUROC	0.720 (0.716–0.721)	0.636 (0.629–0.643)	0.756 (0.747–0.766)	0.699 (0.695–0.709)
	AUPRC	0.128 (0.126–0.131)	0.152 (0.148–0.157)	0.772 (0.763–0.780)	0.499 (0.484–0.511)
Calibration	Slope	1.033 (1.019–1.053)	0.623 (0.592–0.658)	1.227 (1.177–1.287)	0.999 (0.962–1.041)
	Intercept	0.040 (‒0.007, 0.092)	‒0.511 (‒0.593, ‒0.426)	0.184 (0.158–0.215)	‒0.424 (‒0.454, ‒0.394)
Clinical Utility	Net benefit at incidence thresholda	n/a	0.022 (0.020–0.022)b	n/a	0.065 (0.061–0.070)b

All measures presented as the median and interquartile range

AUPRC area under the precision-recall curve; AUROC area under the receiver operating characteristic; GoDARTS Genetics of Diabetes Audit and Research in Tayside Scotland

^aIncidence threshold (GoDARTS): Incident Neuropathic pain = 10.7%, Resolved Neuropathic Pain = 23.7%

^bAdjusted for calibration